Sevuparin

DRUG4 trials

Sponsors

Modus Therapeutics AB, Imperial College London

Conditions

Chronic kidney diseaseMalariaSafety and TolerabilitySickle-Cell Disease

Phase 1

Placebo-controlled Study to Determine the Safety and Tolerability of Subcutaneous Doses of Sevuparin

CompletedNCT03853421

Modus Therapeutics ABSafety and Tolerability

Start: 2019-02-06End: 2019-05-06Updated: 2019-07-16

Phase I Safety and Dose finding Trial of Sevuparin in children with severe malaria

RecruitingPACTR202007890194806

Imperial College LondonMalaria

Start: 2020-07-15Target: 20Updated: 2026-08-03

Phase 2

Sevuparin Infusion for the Management of Acute VOC in Subjects With SCD

CompletedNCT02515838

Modus Therapeutics ABSickle-Cell Disease

Start: 2015-07-31End: 2019-05-31Updated: 2019-07-16

A Phase II Study with Sevuparin in Subjects with Chronic Kidney Disease

RecruitingCTIS2024-513864-24-00

Modus Therapeutics ABChronic kidney disease

Start: 2024-11-28Target: 60Updated: 2025-11-03

Related Papers

Sevuparin for the treatment of acute pain crisis in patients with sickle cell disease: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.

2021-05-0127 citations

Sevuparin Blocks Sickle Blood Cell Adhesion and Sickle-Leukocyte Rolling on Immobilized L-Selectin in a Dose Dependent Manner

Blood2016-12-023 citations